Clinical trials: Atopic Skin
Atopic Dermatitis
Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
This is a randomized, double-blind, double-dummy, active-controlled, multi-center study to assess the efficacy and safety of abrocitinib 200 mg (2 x 100 mg tablets) administered orally QD compared with dupilumab 300 mg…
- Trial name
- NCT04345367
- Testing
- Abrocitinib 200 mg, Dupilumab 300 mg
- Where
- 151 sites in United States, Australia and 13 more
- Volunteers
- 727 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic
Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: Change in disease activity after 16 and 24 weeks Change in subject and family quality of…
- Trial name
- NCT05527964
- Where
- Czechia
- Volunteers
- 146 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants…
- Trial name
- NCT05277571
- Testing
- UCB1381
- Where
- 16 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Atopic Dermatitis (AD)
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500.
- Trial name
- NCT06810050
- Testing
- CGB-500 with 0.5% tofacitinib, CGB-500 Ointment with 1% tofacitinib
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- CAGE Bio Inc.
Atopic Dermatitis
A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
This clinical trial aims to explore whether the drug ZL-82 tablets can be used to treat moderate to severe atopic dermatitis in adults, and to understand the safety and tolerability of the drug.
- Trial name
- NCT07193589
- Testing
- The high-dose group of ZL-82 tablets, The low-dose group of ZL-82 tablets
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Atopic Dermatitis
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
- Trial name
- RE-UNITE AD (NCT06988605)
- Where
- 108 sites in United States, Germany and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
The purpose of this research study is to determine whether the study drug, EDP1815, is safe and effective in the treatment of atopic dermatitis compared with placebo.
- Trial name
- NCT05121480
- Testing
- EDP1815
- Where
- 59 sites in United States, Australia and 4 more
- Volunteers
- 421 people
- Sponsor
- Evelo Biosciences, Inc.
Atopic Dermatitis (AD)
To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD
A multicenter, randomized, double-blind, vehicle-controlled, parallel group trial to demonstrate the superiority of 0.3% and 1% OPA-15406 ointment to vehicle in pediatric subjects with AD.
- Trial name
- NCT05650320
- Testing
- 0.3% OPA-15406 Ointment, 1% OPA-15406 Ointment, 0% OPA-15406 vehicle
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Otsuka Beijing Research Institute
Atopic Dermatitis
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
- Trial name
- NCT05032859
- Testing
- tapinarof cream, 1%, vehicle cream
- Where
- 62 sites in United States, Canada
- Volunteers
- 406 people
- Sponsor
- Organon and Co
Atopic Dermatitis (AD)
A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis
To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).
- Trial name
- NCT07173478
- Testing
- OPA-15406, Vehicle
- Where
- Japan
- Volunteers
- 156 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Dermatitis, Atopic
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive
This study is divided into two parts: Part A of the study is double blinded, randomized, placebo-controlled and aims to assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamic (PD) effect of a single…
- Trial name
- NCT05590338
- Testing
- GSK1070806
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dermatitis
Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis
Considering the pathogenesis of several allergic skin diseases to be investigated in this study as well as the pharmacodynamic mechanisms of the association of dexamethasone and clemastine fumarate, it is believed that the…
- Trial name
- NCT01125761
- Testing
- dexamethasone 0.5 mg and 1.0 mg clemastine cream, Dexamethasone 0,5 mg cream
- Where
- 2 sites in Brazil
- Sponsor
- Azidus Brasil
Atopic Dermatitis
A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD)
Sleep disturbance is very common in patients with atopic dermatitis (AD) and is a major factor leading to impaired quality of life. Nocturnal scratching is one of the factors causing sleep disturbance in AD patients.
- Trial name
- NCT04262791
- Testing
- Wrist Actigraphy Device, Sleep Headband
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AbbVie
Psoriasis, Atopic Dermatitis
An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis
CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics.
- Trial name
- NCT06275659
- Testing
- CT-100-004-A, CT-100-004-B
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Click Therapeutics, Inc.
Hemay005, Atopic Dermatitis
A Study of Hemay005 in Adult With Atopic Dermatitis
A multicenter, randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of Hemay005 tablet in the treatment of moderate to severe atopic dermatitis.
- Trial name
- NCT05769946
- Testing
- Hemay005
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Atopic Dermatitis
The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
The purpose of the study is to evaluate the effect of ruxolitinib cream on itch in participants with Atopic Dermatitis.
- Trial name
- SCRATCH-AD (NCT04839380)
- Testing
- ruxolitinib cream
- Where
- 2 sites in Canada
- Volunteers
- 49 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants
The primary objective of the study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) dose in a vial compared to a prefilled syringe in healthy participants.
- Trial name
- NCT06268860
- Testing
- Rocatinlimab vial injection, Rocatinlimab prefilled syringe
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Amgen
Atopic Dermatitis
Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of baricitinib as monotherapy in participants with moderate to severe atopic dermatitis.
- Trial name
- BREEZE-AD2 (NCT03334422)
- Testing
- Baricitinib
- Where
- 80 sites in Argentina, Australia and 8 more
- Volunteers
- 615 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis, Eczema, Atopic
Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive Skin.
Multicentric, double blind, randomized, comparative study with two parallel group: study group vs placebo group. 5 visits: inclusion visit [day (D) 0] and 4 follow-up visits (D30, D60, D90, and D120).
- Trial name
- NCT05575882
- Testing
- Skin hydration, Barrier function measurement, Potential of hydrogen measurement (pH)
- Where
- 3 sites in Argentina, India and 1 more
- Volunteers
- 100 people
- Sponsor
- NAOS Argentina S.A.